Chemistry:PD-0299685
From HandWiki
PD-0299685 is a gabapentinoid (α2δ subunit-containing voltage-gated calcium channel blocker) which was under development for the treatment of insomnia and vasomotor symptoms (hot flashes) related to menopause as well as interstitial cystitis.[1][2][3] It is taken orally.[1] PD-0299685 was under development by Pfizer.[1] It reached phase 2 clinical trials prior to the discontinuation of its development.[1]
See also
- List of investigational insomnia drugs
- Atagabalin (PD-0200390)
References
- ↑ 1.0 1.1 1.2 1.3 "PD 0299685". 5 November 2023. https://adisinsight.springer.com/drugs/800021998.
- ↑ "Undertreatment of menopausal symptoms and novel options for comprehensive management". Current Medical Research and Opinion 25 (11): 2689–2698. November 2009. doi:10.1185/03007990903240519. PMID 19775194.
- ↑ "Investigation of a Ca2+ channel α2δ ligand for the treatment of interstitial cystitis: results of a randomized, double-blind, placebo controlled phase II trial". The Journal of Urology 188 (3): 817–823. September 2012. doi:10.1016/j.juro.2012.05.010. PMID 22818144.
 |  |
